| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
Sector: Pharmaceuticals
| Eli Lilly is experiencing significant advancements in product development, particularly highlighted by successful trials of next-generation drugs and effective weight-loss medicines. The strong focus on genetic medicines for rare diseases and the diversification of its product pipeline further enhance its growth prospects. However, market competition in weight-loss drug development remains intense, potentially impacting Eli Lilly's market share. Overall, the company's strategic advancements position it well in the evolving pharmaceutical landscape. |
| The price action of Eli Lilly (LLY) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at 2.9 is extremely bullish. The market sentiment at 0.5 is modestly bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next. LLY is likely to move up since both trend sentiment and market sentiment are positive. The positive sentiment force for sector is at 1.5, and the negative at -1 on 2026-06-09. The forces of Sentiment towards Fundamentals (3.4), Stock Price Trend (2.9), Sector Price Trend (1.4), Valuation Sentiment (1.3), and Option Sentiment (0.8) will drive up the price. The forces of Price Level Sentiment (-0.5), and Market Risk Appetite (-5.3) will drive down the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice notifications on Market Movers
| LLY | ||||||||||||||
| Date | Attention | Price | StdDev | Price Level | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-09 | 0%(0.1%) | 1144.04 | 4.52% | 88 | -0.43% | 0.71% | 2.9 | -0.4 | 0.9% | 0.6 | Long | 65% | 3.4 | -1 |
| 2026-06-08 | 1%(0.1%) | 1148.97 | 4.59% | 94 | 1.41% | 0.76% | 3 | -0.2 | 1.2% | 0.5 | Wait | 50% | 3.2 | 5.1 |
| 2026-06-07 | 0%(0%) | 2.2 | -0.2 | -0.1 | 2.7 | -1 | ||||||||
| 2026-06-06 | 0%(0%) | 2.2 | -0.2 | -0.1 | 3.1 | -1 | ||||||||
| 2026-06-05 | 0%(0%) | 1133.01 | 4.71% | 90 | 0.69% | 0.85% | 2.2 | -0.3 | 2.1% | -0.1 | Wait | 50% | 3.4 | -1 |
| 2026-06-04 | 0%(0%) | 1125.3 | 4.6% | 92 | 3.92% | 1% | 1.7 | 0.3 | 2.3% | 0.3 | Long | 55% | 3.5 | 5 |
| 2026-06-03 | 0%(0%) | 1082.87 | 4.52% | 76 | 1.69% | 0.57% | 1.1 | 0.1 | 0.8% | 0.5 | Long | 55% | 4.2 | 2.7 |
| 2026-06-02 | 0%(0%) | 1064.84 | 4.54% | 69 | -1.58% | 0.73% | 1.2 | -0.4 | 1.1% | 0.6 | Wait | 50% | 4.8 | -1 |
| 2026-06-01 | 0%(0.1%) | 1081.96 | 4.55% | 80 | -2.17% | 0.73% | 1.6 | -0.2 | 1.7% | 1 | Long | 65% | 4.9 | -1 |
| 2026-05-31 | 0%(0.1%) | 3 | -0.2 | 1.3 | 5 | -1 | ||||||||
| Long is the preferred trading strategy with 65% chance of being right. Both trend sentiment and hourly trend are very strong. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||
| Analysis | ||
| ● Eli Lilly (LLY) – Equity Research Report Tue. Mar 17, 2026 | ||
| Market News | ||
| 1 (8) Eli Lilly stock rises after late-stage trial of next-generation weight-loss drug Eli Lilly shares gained on Monday, after a late-stage trial of its next-generation weight-loss drug impressed analysts. (https://www.marketwatch.com/) Mon. Jun 8, 2026 | ||
| 2 (8) Eli Lilly stock rises after late-stage trial of next-generation weight-loss drug Eli Lilly shares gained on Monday, after a late-stage trial of its next-generation weight-loss drug impressed analysts. (https://www.marketwatch.com/) Mon. Jun 8, 2026 | ||
| 3 (5) Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising. Eli Lilly and Novo Nordisk both shared good news on their weight-loss drug offerings but the stocks had very different reactions early Monday. (https://www.barrons.com/) Mon. Jun 8, 2026 | ||
| 4 (5) Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising. Eli Lilly and Novo Nordisk both shared good news on their weight-loss drug offerings but the stocks had very different reactions early Monday. (https://www.barrons.com/) Mon. Jun 8, 2026 | ||
| 5 (5) Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising. Eli Lilly and Novo Nordisk both shared good news on their weight-loss drug offerings but the stocks had very different reactions early Monday. (https://www.barrons.com/) Mon. Jun 8, 2026 | ||
| 6 (5) Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising. Eli Lilly and Novo Nordisk both shared good news on their weight-loss drug offerings but the stocks had very different reactions early Monday. (https://www.barrons.com/) Mon. Jun 8, 2026 | ||
| 7 (6) A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk. Zealand Pharma's stock is cratering today after disappointing results from a late-stage trial of its GLP-1 dual-receptor agonist drug. (https://www.fool.com/) Mon. Jun 8, 2026 | ||
| 8 (5) Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising. Eli Lilly and Novo Nordisk both shared good news on their weight-loss drug offerings but the stocks had very different reactions early Monday. (https://www.barrons.com/) Mon. Jun 8, 2026 | ||
| 9 (8) Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drug Eli Lilly shares jumped in premarket trade on Monday, after a late-stage trial of its next-generation weight-loss drug impressed analysts. (https://www.marketwatch.com/) Mon. Jun 8, 2026 | ||